A Precision Approach to Herpes Outbreaks

Q-REStrain is a personalized oligonucleotide infusion designed to inhibit Herpes Simplex Virus replication

Investigational, evidence-emerging

Investigational, evidence-emerging

Investigational, evidence-emerging

How it works

Confirm HSV

PCR/serology

Create your oligonucleotide infusion

Sequence-specific design tailored to you

Infusion + follow-up

Monitor over 4–6+ months

Is it right for me?

• Frequent outbreaks despite standard care

• Prefer a precision, non-antiviral strategy

• Comfortable with personalized non-FDA approved options

*Not FDA-approved for HSV; evidence is preliminary. We provide detailed, informed consent and coordinate with your primary provider(s).

What to Expect

Visit 1

Eligibility consult + review of labs

Visit 2

In-office infusion day

Visit 1

Check-ins over 4–6+ months; repeat dosing only if indicated

Clinician Oversight

Led by Lisbeth Roy, DO, Doctors Studio Founder & CEO. We coordinate care with your current providers and maintain safer-sex and evidence-based guidance.

FAQ

Is this a cure?

Q-REstrain is designed to target viral replication at the genetic level, to reduce outbreak frequency and severity. However, this is not a cure, and outcomes vary between individuals. We work with you to set realistic expectations based on current evidence.

How soon can I receive it?

After eligibility, lab confirmation, and Q-REstrain blood draw, it takes 4-6 weeks to receive the personalized oligonucleotide therapy solution in the clinic.

Do I stop antivirals?

Only with clinician guidance; we co-manage care per CDC best practices.

Note: This investigational treatment uses patient-specific nucleic acid (targeted microRNA) therapy designed to bind defined viral gene sequences and interfere with HSV replication.

Check Eligibility. Contact Us Today!